AstraZeneca reported a sharp rise in third-quarter profit on Friday, driven by strong demand for its cancer medicines. The British pharmaceutical company also announced a restructuring programme designed to deliver $1.5 billion (€1.34 billion) in annual savings, with most of the money intended for investment in new treatments.
The results make this a significant development in Europe news because they combine strong pharmaceutical growth with a long-term plan that could affect the company’s workforce, research pipeline and investment priorities.
Strong quarterly performance led by oncology
AstraZeneca said profit after tax reached $3.12 billion (€2.79 billion) between July and September 2026, an increase of 23% compared with the same period a year earlier. Revenue rose 7% to $16.2 billion (€14.5 billion).
The company’s oncology division remained the main engine of growth. Cancer medicines generated $7.8 billion (€6.99 billion) in sales, up 17% year on year and representing 48% of total revenue.
Growth was supported by several established medicines, particularly:
- Tagrisso, used in the treatment of lung cancer;
- Imfinzi, an immunotherapy medicine; and
- A wider portfolio of cancer treatments supporting AstraZeneca’s late-stage development strategy.
Core earnings per share, which exclude certain costs including restructuring expenses and the amortisation of acquired medicines, increased 17% to $2.79.
AstraZeneca savings plan to reshape the business
The company’s new programme, called “Reshaping for Sustainable Growth”, is intended to generate $1.5 billion in annual savings. AstraZeneca said those savings would primarily be reinvested in research and development, including more than 180 projects currently in development.
The plan is expected to cost up to $2 billion (€1.79 billion) in one-off restructuring charges. The company said it expects the programme to be largely completed by the end of 2029.
No job losses were announced. However, the scale of the restructuring means employment changes remain possible as the company reallocates resources across its operations. AstraZeneca said the purpose of the programme was to direct funding towards medicines and technologies with the greatest potential for future growth.
Chief executive Pascal Soriot said the company remained on course to meet its 2030 ambitions, citing late-stage medicines and developing technologies as key parts of its strategy.
Older medicines face generic competition
The strong overall performance came despite pressure on some established products. Sales of Farxiga, which is used to treat diabetes as well as heart and kidney conditions, dropped 25% to $1.6 billion (€1.43 billion) after cheaper generic alternatives entered the United States market.
Brilinta, a blood-thinning medicine, also faced the loss of patent protection. These developments illustrate the challenge facing major pharmaceutical companies: revenue from successful medicines can decline rapidly once exclusivity ends, increasing the need for new products.
AstraZeneca is also dealing with China’s volume-based procurement system. The state purchasing scheme uses large orders to negotiate lower prices from pharmaceutical companies, putting pressure on the prices and margins of some medicines.
Company maintains 2026 outlook
AstraZeneca confirmed its financial guidance for 2026. It expects revenue to rise by a mid-to-high single-digit percentage and core earnings per share to grow by a low double-digit percentage, excluding the effect of currency movements.
The company also maintained its target of generating $80 billion (€71.7 billion) in annual revenue by 2030. That compares with nearly $59 billion (€52.9 billion) in 2025. AstraZeneca expects the United States to account for half of its 2030 revenue.
The company’s increasing focus on the American market was underlined by its addition of a direct share listing in New York in February. At the same time, AstraZeneca has pledged to invest $15 billion (€13.4 billion) in China by 2030, demonstrating the importance of both markets to its long-term plans.
Research pipeline remains central to strategy
AstraZeneca said it had recorded 12 positive late-stage trial results so far in 2026. Late-stage clinical trials are among the final steps before a medicine can seek regulatory approval, although positive results do not guarantee that a treatment will ultimately be authorised.
The company is also developing a weight-loss treatment intended to compete in a market dominated by medicines such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro. Success in this area could give AstraZeneca another major growth opportunity, but the development and approval of new medicines remain subject to clinical and regulatory review.
Shares in AstraZeneca rose by more than 4.5% in early trading following the results, reflecting the market’s initial response to the stronger profit figures and continued confidence in the company’s pipeline.
What the results mean for Europe’s pharmaceutical sector
AstraZeneca’s update highlights several wider issues affecting European pharmaceutical companies:
- Strong oncology demand continues to support growth in the sector.
- Patent expiries and generic competition can quickly reduce sales of established medicines.
- Companies are using restructuring to redirect resources towards research and development.
- China’s procurement policies and pricing systems remain important commercial factors.
- The United States continues to be a major source of pharmaceutical revenue and investment.
For European investors and policymakers, the results also underline the strategic importance of maintaining pharmaceutical research capacity, manufacturing investment and access to global markets. AstraZeneca’s plans do not represent a European Union decision or new EU regulation; they are corporate decisions by a company headquartered in the United Kingdom.
What happens next?
AstraZeneca will now need to implement its savings programme over the coming years while continuing to fund clinical development and regulatory submissions. The company’s performance will depend on whether newer medicines can offset declines in products affected by generic competition and patent expiry.
Investors will also be watching progress towards the 2030 revenue target, developments in the weight-loss treatment programme and the commercial effects of procurement policies in China.
The immediate takeaway from this Europe news update is that AstraZeneca is using strong cancer-drug sales to finance a long-term transformation. Its next challenge will be converting research investment into approved medicines while managing restructuring costs and pressure on older products.